MX9701510A - Formulaciones liquidas de inmunoglobulina. - Google Patents

Formulaciones liquidas de inmunoglobulina.

Info

Publication number
MX9701510A
MX9701510A MX9701510A MX9701510A MX9701510A MX 9701510 A MX9701510 A MX 9701510A MX 9701510 A MX9701510 A MX 9701510A MX 9701510 A MX9701510 A MX 9701510A MX 9701510 A MX9701510 A MX 9701510A
Authority
MX
Mexico
Prior art keywords
immunoglobulin
immunoglobulin formulations
liquid immunoglobulin
preparations
amphiphilic stabilizers
Prior art date
Application number
MX9701510A
Other languages
English (en)
Inventor
Rene Brugger
Katharina Gennari
Gerhard Hodler
Bernard Wust
Original Assignee
Red Cross Found Cent Lab Blood
Transfusion Service Src
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Red Cross Found Cent Lab Blood, Transfusion Service Src filed Critical Red Cross Found Cent Lab Blood
Publication of MX9701510A publication Critical patent/MX9701510A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen preparaciones de inmunoglobulinas, particularmente preparaciones líquidas de inmunoglobulina G, para infusion intravenosa, que son estabilizadas contra la formacion de dímeros por medio de la adicion de uno o más estabilizadores anfifílicos. Los estabilizadores anfifílicos preferidos son los derivados delácido nicotínico, particularmente la nicotinamida, y los alfa-aminoácidos naturales que tienen una cadena lateral lipofílica, por ejemplo, fenilalanina, prolina, leucina e isoleucina.
MX9701510A 1994-09-08 1995-09-07 Formulaciones liquidas de inmunoglobulina. MX9701510A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9418092A GB9418092D0 (en) 1994-09-08 1994-09-08 Organic compounds
PCT/EP1995/003522 WO1996007429A1 (en) 1994-09-08 1995-09-07 Liquid immunoglobulin formulations

Publications (1)

Publication Number Publication Date
MX9701510A true MX9701510A (es) 1997-05-31

Family

ID=10761028

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701510A MX9701510A (es) 1994-09-08 1995-09-07 Formulaciones liquidas de inmunoglobulina.

Country Status (27)

Country Link
US (1) US5871736A (es)
EP (1) EP0779818B1 (es)
JP (1) JP3004729B2 (es)
KR (1) KR100370631B1 (es)
CN (1) CN1157572A (es)
AT (1) ATE246005T1 (es)
AU (1) AU700788B2 (es)
BR (1) BR9508821A (es)
CA (1) CA2197432C (es)
CZ (1) CZ285967B6 (es)
DE (1) DE69531400T2 (es)
DK (1) DK0779818T3 (es)
FI (1) FI970603A (es)
GB (1) GB9418092D0 (es)
HU (1) HU223668B1 (es)
IL (1) IL115226A (es)
MX (1) MX9701510A (es)
NO (1) NO971016D0 (es)
NZ (1) NZ292919A (es)
PL (1) PL182738B1 (es)
PT (1) PT779818E (es)
RO (1) RO118568B1 (es)
RU (1) RU2158605C2 (es)
SK (1) SK282332B6 (es)
TW (1) TW407056B (es)
WO (1) WO1996007429A1 (es)
ZA (1) ZA957583B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6139838A (en) * 1996-09-06 2000-10-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Tissue plasminogen activator medicinal composition
GB9705810D0 (en) * 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6875432B2 (en) * 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
PL1610820T5 (pl) 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
SI1698640T2 (sl) 2003-10-01 2019-08-30 Kyowa Hakko Kirin Co., Ltd. Postopek za stabiliziranje protitelesa in stabiliziran pripravek protitelesa tipa raztopina
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
AU2014201388C1 (en) * 2006-12-21 2017-02-02 Amgen Inc. Stable Buffered Formulations Containing Polypeptides
CA2672902C (en) * 2006-12-21 2012-11-27 Amgen Inc. Formulations
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
CN101687046B (zh) 2007-07-10 2012-12-26 株式会社美地拓斯 稳定性改善的肉毒毒素药物液体组合物
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
RU2011140498A (ru) * 2009-03-06 2013-04-20 Дженентек, Инк. Препарат антител
TWI445714B (zh) 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
US9241897B2 (en) 2010-02-04 2016-01-26 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
KR101807894B1 (ko) 2010-03-01 2017-12-12 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
FR2961107B1 (fr) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
JP6055412B2 (ja) 2010-09-17 2016-12-27 バクスアルタ ゲーエムベーハー 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化
JP6224586B2 (ja) * 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
CA2923844C (en) 2013-09-11 2022-07-26 Arsia Therapeutics, Inc. Liquid protein formulations containing organophosphates
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2016054259A1 (en) 2014-10-01 2016-04-07 Arsia Therapeutics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
IL301681A (en) * 2020-09-27 2023-05-01 Emergent Biosolutions Canada Inc Hyperimmune globulin preparations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362661A (en) * 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4360457A (en) * 1979-08-30 1982-11-23 Teijin Limited S-Sulfonated immunoglobulin composition having a high monomer content and a process for production thereof
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
JPS60120823A (ja) * 1983-12-02 1985-06-28 Green Cross Corp:The ＩｇＧ単量体
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) * 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
HUT54308A (en) * 1989-04-04 1991-02-28 Lilly Co Eli Process for producing immunoglobulin conjugates and medicaments comprising same
JP2942412B2 (ja) * 1991-12-26 1999-08-30 鐘紡株式会社 化粧料

Also Published As

Publication number Publication date
CZ285967B6 (cs) 1999-12-15
FI970603A0 (fi) 1997-02-12
GB9418092D0 (en) 1994-10-26
JPH10502938A (ja) 1998-03-17
ATE246005T1 (de) 2003-08-15
US5871736A (en) 1999-02-16
CA2197432C (en) 2008-11-04
AU700788B2 (en) 1999-01-14
CN1157572A (zh) 1997-08-20
CA2197432A1 (en) 1996-03-14
SK282332B6 (sk) 2002-01-07
IL115226A (en) 1999-08-17
KR100370631B1 (ko) 2003-04-18
PL318265A1 (en) 1997-05-26
HUT77122A (hu) 1998-03-02
DE69531400T2 (de) 2004-05-27
PT779818E (pt) 2003-11-28
NZ292919A (en) 1998-12-23
AU3522995A (en) 1996-03-27
FI970603A (fi) 1997-02-12
SK30097A3 (en) 1997-10-08
BR9508821A (pt) 1997-12-23
DE69531400D1 (de) 2003-09-04
EP0779818B1 (en) 2003-07-30
WO1996007429A1 (en) 1996-03-14
CZ68497A3 (en) 1997-06-11
RO118568B1 (ro) 2003-07-30
DK0779818T3 (da) 2003-11-24
IL115226A0 (en) 1995-12-31
RU2158605C2 (ru) 2000-11-10
HU223668B1 (hu) 2004-11-29
ZA957583B (en) 1997-03-10
PL182738B1 (pl) 2002-02-28
TW407056B (en) 2000-10-01
EP0779818A1 (en) 1997-06-25
NO971016L (no) 1997-03-05
NO971016D0 (no) 1997-03-05
JP3004729B2 (ja) 2000-01-31

Similar Documents

Publication Publication Date Title
MX9701510A (es) Formulaciones liquidas de inmunoglobulina.
WO1994027587A3 (en) Sustained antiepileptic therapy
GR3034924T3 (en) Novel peptide derivatives
IL109144A (en) Glycoprotein IIB/IIIA inhibiting 4-pyridylamino heterocyclic derivatives process for their preparation and pharmaceutical compositions containing them
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
ES2032382T3 (es) Metodo para preparar un medicamento para la prevencion o tratamiento de la endometriosis.
SE8402560L (sv) Farmaceutisk komposition
GR3034204T3 (en) Lipopolyamines as transfection agents and pharmaceutical uses thereof
UA39172C2 (uk) Похідні 2-(2,6-дигалофеніламіно) фенілоцтової кислоти і спосіб їх одержання
GB9206244D0 (en) Cytotoxic compound from a marine sponge
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
WO1996020208A3 (de) Neues cholesterolderivat für den liposomalen gentransfer
AU697486B2 (en) Combination preparations comprising a quinoxaline and a nucleoside
PL308203A1 (en) Synthesis of n-acetloneuraminic acid derivatives
AU3184493A (en) New pseudopeptide compounds having bradykinin-antagonist activity, process for preparing them and pharmaceutical compositions containing them
BG104452A (en) New derivatives of the methylenebisphosphonic acid
WO2001021140A3 (de) Kosmetische und/oder pharmazeutische zubereitungen
UA32583C2 (uk) Похідні арилтіоалкілтіопіридину
MY104782A (en) Glutaric acid derivatives and preparations thereof.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: CSL BEHRING AG

HC Change of company name or juridical status

Owner name: CSL BEHRING AG

HC Change of company name or juridical status

Owner name: CSL BEHRING AG

MM Annulment or lapse due to non-payment of fees